Long-term therapy with bevacizumab in a young patient affected by NF-2

Olga Nigro(Fondazione IRCCS Istituto Nazionale dei Tumori), Graziella Pinotti(Medica (Italy)), Matteo B. Suter(Ospedale di Circolo e Fondazione Macchi), Tiziana Tartaro(Ospedale di Circolo e Fondazione Macchi), Alessandro Tuzi(Ospedale di Circolo e Fondazione Macchi), A. Giaquinto(Ospedale di Circolo e Fondazione Macchi)
Anti-Cancer Drugs
January 19, 2019
10.1097/cad.0000000000000732
Cited by 2

Related Papers

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
|Blood|2003|490
Autografting Followed by Nonmyeloablative Immunosuppressive Chemotherapy and Allogeneic Peripheral-Blood Hematopoietic Stem-Cell Transplantation as Treatment of Resistant Hodgkin’s Disease and Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2000|228